Skip to content
Nabeel Badri, M.B.Ch.B.

Nabeel Badri, M.B.Ch.B.

Cancer

UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Accepting New Patients

About Me

I am a medical oncologist at the Wilmot Cancer Institute, University of Rochester Medical Center. I am specialized in treating gastroenterology malignancies. My primary research interest has focused on gastrointestinal malignancies. Currently, I have been involved in various studies/clinical-trials ...
I am a medical oncologist at the Wilmot Cancer Institute, University of Rochester Medical Center. I am specialized in treating gastroenterology malignancies. My primary research interest has focused on gastrointestinal malignancies. Currently, I have been involved in various studies/clinical-trials investigating novel approaches and chemo-therapeutics to treat gastrointestinal cancer.

Conditions I treat:

* Esophageal cancer
* Stomach cancer
* Pancreatic cancer
* Colon cancer
* Rectal cancer
* Anal cancer
* Neuroendocrine tumors and carcinoid tumors
* Liver cancer: Hepatocellular carcinoma (HCC)
* Bile duct cancer
* Cholangiocarcinoma
* Appendiceal cancer and tumors

Certified Specialties

Internal Medicine - American Board of Internal Medicine

Medical Oncology - American Board of Internal Medicine

Faculty Appointments

Assistant Professor - Department of Medicine, Hematology/Oncology (SMD)

Credentials

Residency & Fellowship

Fellowship, Hematology & Oncology, University of Rochester Medical Center. 2018 - 2020

Fellowship, Hematology & Oncology, Howard University Hospital. 2017 - 2018

Residency, Internal Medicine, Texas Tech University Health Sciences Center-EP. 2015 - 2017

Internship, Internal Medicine, Texas Tech University Health Sciences Center-EP. 2014 - 2015

Education

MBBCH | Al-Kindy College of Medicine (Iraq). 2007

Awards

Fellow in Clinical Research Methodology Training Program, University of Rochester. 2022

Biochemistry Honor Roll. 2003

Pathophysiology Honor Roll. 2003

Research

Clinical Trials

The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing The Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients With Locally Advanced Rectal Cancer

Lead Researcher: Nabeel Badri

This phase II trial compares the effect of irinotecan versus oxaliplatin after long-course chemoradiation in patients with stage II-III rectal cancer. Combination chemotherapy drugs, such as FOLFIRINOX (fluorouracil, irinotecan, leucovorin, and oxali...

Publications

Journal Articles

Brentuximab vedotin demonstrates an objective response in a patient with refractory CD30+ primary mediastinal B-cell lymphoma.

Badri N, Ngamdu KS, Torabi A, Guar S

Journal of cancer research and therapeutics.. 2020 16 (1):183-185. Epub 1900 01 01.

Disparities in breast cancer: a multi-institutional comparative analysis focusing on American Hispanics.

Nahleh Z, Otoukesh S, Mirshahidi HR, Nguyen AL, Nagaraj G, Botrus G, Badri N, Diab N, Alvarado A, Sanchez LA, Dwivedi AK

Cancer medicine. 2018 June 7 (6):2710-2717. Epub 05/07/2018.

Epithelial-Mesenchymal Transition Markers in Breast Cancer and Pathological Responseafter Neoadjuvant Chemotherapy.

Elzamly S, Badri N, Padilla O, Dwivedi AK, Alvarado LA, Hamilton M, Diab N, Rock C, Elfar A, Teleb M, Sanchez L, Nahleh Z

Breast cancer : basic and clinical research.. 2018 12 :1178223418788074. Epub 08/01/2018.

Use of non-selective ?-blockers is associated with decreased tumor proliferative indices in early stage breast cancer.

Montoya A, Amaya CN, Belmont A, Diab N, Trevino R, Villanueva G, Rains S, Sanchez LA, Badri N, Otoukesh S, Khammanivong A, Liss D, Baca ST, Aguilera RJ, Dickerson EB, Torabi A, Dwivedi AK, Abbas A, Chambers K, Bryan BA, Nahleh Z

Oncotarget.. 2017 January 248 (4):6446-6460. Epub 1900 01 01.

Prevalence of Low Vitamin D in Patients with Breast Cancer in a Predominantly Hispanic Population at the American-Mexican Border.

Farrag SE, Dwivedi AK, Otoukesh S, Badri NJ, Sanchez LA, Nahleh ZA

Nutrition and cancer.. 2017 69 (6):819-824. Epub 07/18/2017.

Diffuse large B-cell non-Hodgkin's lymphoma and osteosclerotic myeloma with features of POEMS syndrome.

Ngamdu KS, Torabi A, Badri N, Teleb M, Gaur S

Proceedings. 2016 July 29 (3):306-8. Epub 1900 01 01.

Seronegative Neuromyelitis Optica: A Case Report of a Hispanic Male.

Badri N, Teleb M, Syed S, Wardi M, Porres-Aguilar M, Cruz-Flores S

Case reports in neurology.. 2016 8 (2):102-7. Epub 05/24/2016.

Ratings & Reviews

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.